4//SEC Filing
Rhodes Jason P 4
Accession 0001415889-24-005780
CIK 0001818794other
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 7:15 PM ET
Size
35.6 KB
Accession
0001415889-24-005780
Insider Transaction Report
Form 4
Rhodes Jason P
Director
Transactions
- Sale
Common Stock
2024-02-26$23.98/sh−64,783$1,553,496→ 6,151,467 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.68/sh−2,216$54,691→ 877,806 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$25.25/sh−2,430$61,358→ 5,698,091 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$24.83/sh−13,109$325,496→ 864,697 total(indirect: See footnote) - Sale
Common Stock
2024-02-26$23.98/sh−5,580$133,808→ 903,527 total(indirect: See footnote) - Sale
Common Stock
2024-02-26$23.59/sh−136,312$3,215,600→ 6,216,250 total(indirect: See footnote) - Sale
Common Stock
2024-02-26$23.59/sh−20,205$476,636→ 1,564,932 total(indirect: See footnote) - Sale
Common Stock
2024-02-26$23.98/sh−9,603$230,280→ 1,555,329 total(indirect: See footnote) - Sale
Common Stock
2024-02-26$23.59/sh−11,736$276,852→ 909,107 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.68/sh−3,821$94,302→ 1,511,053 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$24.83/sh−22,567$560,339→ 1,488,486 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.38/sh−272,923$6,653,863→ 5,878,544 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$24.83/sh−152,244$3,780,219→ 5,700,521 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.68/sh−25,779$636,226→ 5,852,765 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.38/sh−40,455$986,293→ 1,514,874 total(indirect: See footnote) - Sale
Common Stock
2024-02-27$24.38/sh−23,505$573,052→ 880,022 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$25.25/sh−360$9,090→ 1,488,126 total(indirect: See footnote) - Sale
Common Stock
2024-02-28$25.25/sh−210$5,303→ 864,487 total(indirect: See footnote)
Footnotes (12)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).
- [F3]The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.
- [F5]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.
- [F6]The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The reporting person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
- [F7]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.
- [F8]The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001577014
Filing Metadata
- Form type
- 4
- Filed
- Feb 27, 7:00 PM ET
- Accepted
- Feb 28, 7:15 PM ET
- Size
- 35.6 KB